<DOC>
	<DOCNO>NCT00155350</DOCNO>
	<brief_summary>In study , , investigator National Taiwan University Hospital , evaluate efficacy pharmacological therapy target reduce insulin resistance ( pioglitazone ) progression compositional change non-obstructive coronary atherosclerotic plaque coronary calcification serial intravascular ultrasound ( IVUS ) /multi-detector-row compute tomography ( MDCT ) follow-up patient type 2 diabetes non-diabetic metabolic syndrome 2-year period .</brief_summary>
	<brief_title>Treatment Coronary Atherosclerosis Insulin Sensitizers Insulin-Resistant Patients</brief_title>
	<detailed_description>Background : Type 2 diabetes antecedent , metabolic syndrome , important risk factor premature accelerate atherosclerotic cardiovascular disease . However , glycemic control provision endogenous exogenous insulin induce modest statistically significant reduction risk myocardial infarction . We investigator demonstrate use insulin sensitizer , thiazolidinediones , result favorable antiatherosclerotic effect patient type 2 diabetes non-diabetic metabolic syndrome . It become increasingly clear morbidity mortality associate coronary artery disease ( CAD ) often associate lesion obstructive prone rupture , so-called vulnerable plaque . Conventional coronary angiography suitable identify vulnerable plaque . They may detect intravascular ultrasound ( IVUS ) recently develop high-resolution 16-slice multi-detector compute tomography ( MDCT ) . Nevertheless , whether modality could use guide optimize medical treatment CAD never explore medical literature . In study , evaluate efficacy pharmacological therapy target reduce insulin resistance progression compositional change non-obstructive coronary atherosclerotic plaque coronary calcification serial IVUS/MDCT follow-up patient type 2 diabetes non-diabetic metabolic syndrome 2-year period . Methods Expected Results : Patients age ≥18 year conform diagnosis type 2 diabetes metabolic syndrome criterion ATP III objective evidence myocardial ischemia undergo EBCT , MDCT coronary angiography , percutaneous coronary angiography intervention appropriate , IVUS study non-obstructive coronary plaque identify MDCT examination . Patients deem eligible ( one ≥ 20 % &lt; 70 % stenosis least one coronary artery ) randomly assign 1:1 ratio receive pioglitazone ( 30 mg/d ) placebo open-label fashion . Patients type 2 diabetes assign placebo group allow treated insulin sensitizer . The target glycemic control patient type 2 diabetes group reduction HbA1c ≤ 7.0 % . A total 120 patient plan include , follow-up period 2 year . To assess progression coronary atherosclerosis , MDCT coronary angiography/scanning perform baseline 3 , 6 , 12 , 24 month follow-up . Follow-up coronary angiography intravascular ultrasound study perform 6 month patient agree . Blood sample also obtain baseline 3 , 6 , 12 , 24 month follow-up measurement various conventional novel coronary risk factor . We also obtain DNA specimen blood draw baseline genotyping . The primary end-points include change baseline total plaque volume , plaque characteristic ( determine CT-density value morphological feature ) , total coronary calcium score . The secondary end-points include percent change baseline calcium volume score coronary artery , percent change baseline plasma glucose/insulin homeostatic parameter various risk marker , occurrence composite major cardiovascular event ( death cause , non-fatal myocardial infarction , stroke , target vessel revascularization ) . Clinical Significance : This first human study ass antiatherosclerotic effect insulin sensitizer directly visualize atherosclerotic plaque whole coronary tree . It provide u great insight regard evolution coronary plaque technique measure total vulnerability burden coronary artery .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age ≥ 18 year presence type 2 diabetes mellitus metabolic syndrome , currently treat thiazolidinediones . Diagnosis metabolic syndrome determine criterion define National Cholesterol Education Program Adult Treatment Panel III , modify use World Health Organization ( WHO ) propose waist circumference cutpoints Asians . Therefore , require subject three follow criterion : waist circumference &gt; 90 cm men &gt; 80 cm woman ; serum triglyceride &gt; = 150 mg/dl ; highdensity lipoproteincholesterol ( HDLC ) level &lt; 40 mg/dl men &lt; 50 mg/dl woman ; impair fast glucose 110 125 mg/dl ; blood pressure &gt; = 130/85 mmHg treat hypertension . Patients objective documentation myocardial ischemia undergo percutaneous coronary angiography coronary arteriogram show one ≥ 20 % &lt; 70 % stenosis , leave untreated physician ’ discretion , least one coronary artery The baseline MDCT coronary angiogram reveal one discernible plaque ( ) untreated stenting least one coronary artery Ability perform task related glycemic control risk factor management Written inform consent sign Class III IV heart failure Creatinine &gt; 2.0 mg/dl Hepatic disease ( ALT &gt; 3 time upper limit normal ) Poorly control diabetes mellitus ( hemoglobin A1c [ HbA1c ] &gt; 13 % ) Fasting triglyceride &gt; 1000 mg/dl presence moderate glycemic control ( HbA1c &lt; 9.0 % ) Noncardiac illness expect limit survival less two year Current alcohol drug abuse Chronic steroid use judge interfere control diabetes , exceed 10 mg Unable understand cooperate protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>calcification</keyword>
	<keyword>coronary</keyword>
	<keyword>inflammation</keyword>
	<keyword>insulin</keyword>
	<keyword>plaque</keyword>
	<keyword>Coronary calcification</keyword>
	<keyword>Plaque vulnerability</keyword>
</DOC>